<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Dave Knapp]]></title><description><![CDATA[On The Pen ]]></description><link>https://www.onthepen.com/zepbound-news</link><generator>RSS for Node</generator><lastBuildDate>Sat, 12 Sep 2026 15:58:48 GMT</lastBuildDate><atom:link href="https://www.manontheweb.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Quintuple Agonist for Obesity: One Drug, 5 Receptors]]></title><description><![CDATA[Yesterday I dropped something that moved faster than I expected, and the reactions ended up being just as telling as the data itself. An Eli Lilly funded scientist is set to present rodent data at the American Diabetes Association meeting on a quintuple agonist, a five pathway compound that has already edged out Retatrutide in rat weight loss. Retatrutide has been treated as the ceiling by a lot of people in this space, so even early animal data suggesting something may surpass it forces a...]]></description><link>https://www.onthepen.com/post/quintuple-agonist-for-obesity-one-drug-5-receptors</link><guid isPermaLink="false">69ee6f1305a9c74b2790af99</guid><category><![CDATA[Eli Lilly]]></category><category><![CDATA[Retatrutide]]></category><pubDate>Sun, 26 Apr 2026 20:33:34 GMT</pubDate><enclosure url="http://www.youtube.com/watch?v=hZnjS9s6-JY" length="0" type="video"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[HUGE! Employers Can Now Offer Zepbound Through New Lilly Program!]]></title><description><![CDATA[Originally posted on obesity.news  on March 5th, 2026 Something very exciting was announced today that may not look extremely dramatic on the surface but could end up reshaping how millions of Americans access obesity treatment. Affordably. Eli Lilly announced the launch of Lilly Employer Connect , a platform designed to help employers offer obesity treatment coverage for their employees, including Zepbound. Early headlines have focused on a single number. $449 for Zepbound. But it’s...]]></description><link>https://www.onthepen.com/post/huge-employers-can-now-offer-zepbound-through-new-lilly-program</link><guid isPermaLink="false">69b03fb14b8043385bd31eb0</guid><category><![CDATA[Zepbound]]></category><pubDate>Tue, 10 Mar 2026 16:28:14 GMT</pubDate><enclosure url="http://youtu.be/s_iZDocTkfI" length="0" type="video"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[Update: CMS and Eli Lilly Release New Details on Medicare GLP-1 Coverage Pilot]]></title><description><![CDATA[Originally posted on obesity.news  on March 9th, 2026 UPDATED 3/10/26: Patient eligibility requirements have been outlined and can be found at the bottom of this article. The question I have been hearing repeatedly since early January is straightforward. Will Medicare actually start covering GLP-1 medications this summer? New documents from the Centers for Medicare &#38; Medicaid Services, along with a statement from Eli Lilly, suggest that something meaningful could begin in July of 2026, but it...]]></description><link>https://www.onthepen.com/post/update-cms-and-eli-lilly-release-new-details-on-medicare-glp-1-coverage-pilot</link><guid isPermaLink="false">69b03b1c00ff578fc8e958e6</guid><category><![CDATA[Medicare]]></category><pubDate>Tue, 10 Mar 2026 15:46:44 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_ac0626c0a2b243d7bd89c63aa12edc4f~mv2.png/v1/fit/w_1000,h_768,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[GLP-1 Gray Market is Booming]]></title><description><![CDATA[Access is Broken Originally posted on obesity.news  on March 3th, 2026 Big shifts are happening in the GLP-1 world. This week on On The Pen , we break down new federal action targeting pharmacy middlemen, potential FDA moves that could impact compounded semaglutide, and the rise of cash-pay weight loss clinics from companies like Walgreens and Amazon. If you’re navigating GLP-1 access, insurance denials, compounding changes, or wondering where this all heads next — this episode connects the...]]></description><link>https://www.onthepen.com/post/glp-1-gray-market-is-booming</link><guid isPermaLink="false">69a73c01a29c2f981473001f</guid><category><![CDATA[Compound Semaglutide]]></category><pubDate>Tue, 03 Mar 2026 19:59:30 GMT</pubDate><enclosure url="http://youtu.be/iSeAwNR4kWU" length="0" type="video"/><dc:creator>Ann Metz</dc:creator></item><item><title><![CDATA[NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?]]></title><description><![CDATA[On this episode of On the Pen , Dave breaks down Novo Nordisk’s decision to slash list prices for Wegovy  and Ozempic  starting in 2027, alongside new head-to-head data showing tirzepatide  outperforming Novo’s next-gen combo CagriSema  in weight loss. Dave also explores promising early results from triple-agonist drugs and the FDA approval of the Allurion Balloon , highlighting how the obesity treatment landscape is rapidly expanding beyond injections toward more personalized and accessible...]]></description><link>https://www.onthepen.com/post/new-glp3-from-novo-nordisk-better-than-retatrutide</link><guid isPermaLink="false">69a1eccbaac6e7cda917175b</guid><category><![CDATA[GLP-3]]></category><category><![CDATA[Ozempic]]></category><category><![CDATA[Wegovy]]></category><category><![CDATA[Tirzepatide]]></category><pubDate>Fri, 27 Feb 2026 19:15:23 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_5d63517ec3be49a7937e9d74de58a6de~mv2.png/v1/fit/w_1000,h_824,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[Better Blood Sugars, More Weight Loss With Orforglipron VS Rybelsus]]></title><description><![CDATA[Lilly has landed what could be a defining blow in the oral GLP-1 race. In a 52-week Phase 3 trial published Wednesday in The Lancet, Lilly’s small molecule pill orforglipron beat Novo Nordisk’s oral semaglutide across the primary endpoint and all key secondary measures in adults with type 2 diabetes on background metformin. The ACHIEVE-3 study enrolled 1,698 patients across 4 arms and marks the first head-to-head comparison between 2 oral GLP-1 receptor agonists in diabetes. While the trial...]]></description><link>https://www.onthepen.com/post/better-blood-sugars-more-weight-loss-with-orforglipron-vs-rybelsus</link><guid isPermaLink="false">69a1eb9b4882ec6a3ac332f7</guid><category><![CDATA[Orforglipron]]></category><category><![CDATA[Rybelsus]]></category><pubDate>Fri, 27 Feb 2026 19:12:26 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_a99f193ca06348c18a8518f5fb5de775~mv2.png/v1/fit/w_1000,h_720,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[EXCLUSIVE: FDA Removes Suicidal Ideation, Depression Language From Obesity GLP-1 Labels After Class-Wide Review]]></title><description><![CDATA[The FDA has formally removed suicidal ideation and depression language from the labeling of GLP-1 medications approved for obesity, closing out a nearly three year safety signal review that began in 2023. Supplement approval letters issued in late February to Novo Nordisk and Eli Lilly confirm that subsection 5.9, Suicidal Ideation and Behavior, has been removed from the Warnings and Precautions sections of Saxenda, Wegovy, and Zepbound. References to “depression or thoughts of suicide” have...]]></description><link>https://www.onthepen.com/post/exclusive-fda-removes-suicidal-ideation-depression-language-from-obesity-glp-1-labels-after-class</link><guid isPermaLink="false">69a1e92bf9c4f9db166259b7</guid><category><![CDATA[FDA]]></category><category><![CDATA[Novo Nordisk]]></category><category><![CDATA[Zepbound]]></category><category><![CDATA[Wegovy]]></category><category><![CDATA[Saxenda]]></category><pubDate>Fri, 27 Feb 2026 19:06:07 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_c76d7005c23144509ca6de0eea0af1e2~mv2.png/v1/fit/w_1000,h_971,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[MASSIVE Winter Storm Could Spoil Your GLP-1 Meds]]></title><description><![CDATA[Here are the manufacturer recommendations, and what you can do. Originally published on January 22, 2026 on obesity.news Disclaimer: The following information is not medical advice, I am not a Doctor. Please consult with your prescribing physician on all matters related to your prescription drugs. UPDATED 1/22/26 12:57PM to reflect a discrepancy between the Mounjaro and Zepbound packaging relating to refrigerating after reaching room temp. There is a generational winter storm bearing down on...]]></description><link>https://www.onthepen.com/post/massive-winter-storm-could-spoil-your-glp-1-meds</link><guid isPermaLink="false">6973a9d977221e862dd6b0bd</guid><category><![CDATA[Zepbound]]></category><category><![CDATA[Mounjaro]]></category><category><![CDATA[Ozempic]]></category><pubDate>Fri, 23 Jan 2026 17:17:27 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_3511f410d2e04d5da8cc0ca17ed19902~mv2.png/v1/fit/w_606,h_340,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[GLP-1s Over the Counter]]></title><description><![CDATA[Predictions and a Little Bathroom Humor Originally posted on obesity.news  on January 20th, 2026 This episode isn’t really about OTC GLP-1s, it’s about pattern recognition. After 3 solid years studying this industry, Dave recognizes the early signals: deals are made, pharma speaks, regulation moves, and patients benefit. The Zepbound vial story serves as context. It’s less “I told you so” and more “this is how these shifts actually happen.” What’s changing isn’t just access, it’s tone. The...]]></description><link>https://www.onthepen.com/post/glp-1s-over-the-counter</link><guid isPermaLink="false">696fd7f17ec7696eebb6b02e</guid><category><![CDATA[Wegovy]]></category><category><![CDATA[Zepbound]]></category><pubDate>Tue, 20 Jan 2026 20:15:36 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_47d8c5b0a0d64a8cae9dcd3579f3505c~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Ann Metz</dc:creator></item><item><title><![CDATA[Achieve More Weight Loss than GLP-1 Alone]]></title><description><![CDATA[Check out this new procedure, and learn about specifics, timelines, and cost! Originally posted on obesity.news  on January 19th, 2026 WATCH THE INTERVIEW HERE! Your inbox, your DMs, and your doctors office may not be buzzing about weight loss balloons again. Yet. The reality is that current GLP-1 therapies may not be an adequate treatment for many, but may need to be combined with newer treatments and therapies. The gastric balloon is back, and this time, it is not surgery. It is not...]]></description><link>https://www.onthepen.com/post/achieve-more-weight-loss-than-glp-1-alone</link><guid isPermaLink="false">696e85c5df75005811cf6df3</guid><category><![CDATA[Advocacy]]></category><category><![CDATA[Health]]></category><category><![CDATA[Health Tools]]></category><pubDate>Mon, 19 Jan 2026 19:42:36 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_f49b684e249a427ba0b03681bf670e46~mv2.png/v1/fit/w_1000,h_720,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[OTP EXLCUSIVE: Mounjaro and Zepbound MULTI-USE Vials Coming Soon!]]></title><description><![CDATA[Originally posted on obesity.news  on January 15th, 2026 Eli Lilly has secured FDA approval for multi use vials of both Zepbound and Mounjaro, according to newly updated package inserts reviewed by On The Pen . The approvals mark the first time Mounjaro has been cleared for vial based distribution in the United States and represent a notable shift in how Lilly may supply its blockbuster tirzepatide franchise. The changes appear in prescribing information revised in January 2026, without...]]></description><link>https://www.onthepen.com/post/otp-exlcusive-mounjaro-and-zepbound-multi-use-vials-coming-soon</link><guid isPermaLink="false">696a8ee444e01db33a0225cc</guid><category><![CDATA[Zepbound]]></category><category><![CDATA[Mounjaro]]></category><category><![CDATA[FDA]]></category><pubDate>Fri, 16 Jan 2026 19:38:01 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_4009b67a8036415fbd723a8816b95807~mv2.png/v1/fit/w_1000,h_971,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[Why Generic Tirzepatide Won't Be Here Any Time Soon]]></title><description><![CDATA[Originally posted on obesity.news  on January 15th, 2026 The US Patent and Trademark Office has officially declined to review a petition from Empower Pharmacy seeking to invalidate a foundational Eli Lilly patent covering tirzepatide, the active ingredient in Zepbound and Mounjaro. The rejection leaves Lilly’s legal fortress around the GLP-1/GIP agonist intact, for now. This also puts pressure on the only remaining open challenge from BPI Labs. NEVER MISS AN UPDATE! Subscribe to our...]]></description><link>https://www.onthepen.com/post/why-generic-tirzepatide-won-t-be-here-any-time-soon</link><guid isPermaLink="false">696a8cc94240a10d7a7e56c7</guid><category><![CDATA[Tirzepatide]]></category><category><![CDATA[Zepbound]]></category><category><![CDATA[Mounjaro]]></category><category><![CDATA[Eli Lilly]]></category><pubDate>Fri, 16 Jan 2026 19:16:31 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_428c1ecc52c74b7d9d57347e64835837~mv2.png/v1/fit/w_1000,h_644,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[Strive Sues Lilly and Novo in Antitrust Challenge Over GLP-1 Access]]></title><description><![CDATA[Originally posted on obesity.news  on January 14th, 2026 Strive Specialties, a national compounding pharmacy, has filed suit in federal court accusing Eli Lilly and Novo Nordisk of unlawfully shutting down competition in the GLP-1 market. This is not a patent challenge.It  is not a safety enforcement action.It  is an antitrust case about market control. And the complaint lays out a specific theory: that Lilly and Novo did not just outcompete compounders, they systematically excluded them. The...]]></description><link>https://www.onthepen.com/post/strive-sues-lilly-and-novo-in-antitrust-challenge-over-glp-1-access</link><guid isPermaLink="false">696a87e344e01db33a021510</guid><category><![CDATA[Eli Lilly]]></category><category><![CDATA[Novo Nordisk]]></category><category><![CDATA[Strive]]></category><category><![CDATA[Advocacy]]></category><pubDate>Fri, 16 Jan 2026 19:05:08 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_dfefec4c30d047ebafc1e449501cec7f~mv2.png/v1/fit/w_1000,h_614,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[GLP-1 Medicine Meets MariTide and Oprah Changes the Frame]]></title><description><![CDATA[FDA Reversals, Pharma Momentum, and Why Patients Can’t Afford to Be Silent Originally posted on obesity.news  on January 13th, 2026 GLP-1, Maritide, and Oprah, A Week That Felt Different at OTP A lot happened in the broader GLP-1 world this week, but what stood out to me wasn’t just the headlines. It was how Dave kept returning to the same core question on air: what does this actually mean for patients?  Whether he was reacting to regulatory shifts, pharma claims, or mainstream voices...]]></description><link>https://www.onthepen.com/post/glp-1-medicine-meets-maritide-and-oprah-changes-the-frame</link><guid isPermaLink="false">6966a008bbaf501a67d58323</guid><category><![CDATA[Eli Lilly]]></category><category><![CDATA[Novo Nordisk]]></category><category><![CDATA[FDA]]></category><category><![CDATA[MariTide]]></category><pubDate>Wed, 14 Jan 2026 19:18:54 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_4a036b42ba1443369cc7649052277ccc~mv2.png/v1/fit/w_1000,h_720,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Ann Metz</dc:creator></item><item><title><![CDATA[Zepbound Self Pay Prices Drop Across All Doses Effective Today]]></title><description><![CDATA[Original posted at obesity.news/  on Dec 01, 2025 Eli Lilly updated the Zepbound Self Pay Journey Program today and lowered the cash price on every dose. The biggest reduction came at the 5 mg strength, which dropped by $100 from $499 to $399. The 2.5 mg dose is now $299, and all higher doses from 7.5 mg through 15 mg have been standardized at $449. Patients can access these reduced prices through any licensed prescriber, including telehealth platforms like our partners at Shed , or through...]]></description><link>https://www.onthepen.com/post/zepbound-self-pay-prices-drop-across-all-doses-effective-today-1</link><guid isPermaLink="false">696547aa300486d2598da1da</guid><category><![CDATA[Zepbound]]></category><pubDate>Mon, 12 Jan 2026 19:15:30 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_51e67a596da844669cc3e04e4bac1b8a~mv2.jpg/v1/fit/w_1000,h_582,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[Losing 60K Followers, Gaining New Hope]]></title><description><![CDATA[New GLP-1 Data, Alzheimer’s Trials, and Rebuilding @OTPHQ on TikTok Original posted at obesity.news/  on Nov 24, 2025 This Week On The Pen: Gratitude, a TikTok Gut-Punch, and the Next Wave of GLP-1 Data This week’s On The Pen  live podcast opened on an unexpectedly emotional note. During Thanksgiving week, a time Dave framed through the lens of that first, uncertain Thanksgiving; he described losing his TikTok account, a community of nearly 60,000 followers, in a single automated decision. No...]]></description><link>https://www.onthepen.com/post/losing-60k-followers-gaining-new-hope-1</link><guid isPermaLink="false">6965448ad1d562b302fca3c3</guid><category><![CDATA[Novo Nordisk]]></category><category><![CDATA[Semaglutide]]></category><category><![CDATA[Rybelsus]]></category><category><![CDATA[Amycretin]]></category><category><![CDATA[Zepbound]]></category><pubDate>Mon, 12 Jan 2026 19:11:58 GMT</pubDate><enclosure url="http://youtu.be/StOwH8Oesxg" length="0" type="video"/><dc:creator>Ann Metz</dc:creator></item><item><title><![CDATA[Novo Nordisk Finally Got the Win It Needed: Phase 2 Amycretin Results]]></title><description><![CDATA[Original posted at obesity.news/  on Nov 25, 2025 Novo Nordisk needed some good news desperately, and today they got it. After a string of trial setbacks, pulled programs, and rising pressure to prove they can still lead the next era of metabolic medicine, the company finally dropped some extremely positive news. Amycretin, their GLP-1 and amylin combo drug, posted phase two results in people with type two diabetes that are not just strong, they are the game changers for type 2 diabetes. And...]]></description><link>https://www.onthepen.com/post/novo-nordisk-finally-got-the-win-it-needed-phase-2-amycretin-results</link><guid isPermaLink="false">6965424ecca849701e923278</guid><category><![CDATA[Novo Nordisk]]></category><category><![CDATA[Amycretin]]></category><category><![CDATA[Type 2 Diabetes]]></category><category><![CDATA[Tirzepatide]]></category><pubDate>Mon, 12 Jan 2026 18:58:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_a6533a1173a249059bc3834c48d4ef57~mv2.png/v1/fit/w_588,h_330,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[Novo, Are You Listening? Vikingtide is Your Chance to Compete with Tirzepatide.]]></title><description><![CDATA[Original posted at obesity.news/  on Jan 11, 2026 Viking Therapeutics appears to have timed this week’s “Vikingtide” data release deliberately, dropping the long awaited VK2735 Phase 2 data just ahead of JPM 2026 in what many investors are calling a classic “put the tape out” moment. These data have existed in pieces for years. What changed this week is that they are now fully published, peer reviewed, and available for annotation by anyone trying to decide whether VK2735 is merely promising...]]></description><link>https://www.onthepen.com/post/novo-are-you-listening-vikingtide-is-your-chance-to-compete-with-tirzepatide</link><guid isPermaLink="false">69653fedf5c800c966565c40</guid><category><![CDATA[Tirzepatide]]></category><category><![CDATA[Vikingtide]]></category><category><![CDATA[Semaglutide]]></category><pubDate>Mon, 12 Jan 2026 18:48:56 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_5680953325e14b668bad361f5b91b878~mv2.png/v1/fit/w_1000,h_720,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[Novo Nordisk Just Released Semaglutide’s Alzheimer’s Results. Here Is What You Need To Know.]]></title><description><![CDATA[Original posted at obesity.news/  on Nov 24, 2025 I knew when I wrote about the Evoke trials this past weekend that we were standing close to a moment that could go either way. A massive breakthrough or another heartbreak in a field that has already had more heartbreak than almost any disease area. This morning, Novo Nordisk released the top line results from the two year Evoke and Evoke Plus trials in early stage Alzheimer’s. And while the news is mixed, it fell far short of what we were...]]></description><link>https://www.onthepen.com/post/novo-nordisk-just-released-semaglutide-s-alzheimer-s-results-here-is-what-you-need-to-know</link><guid isPermaLink="false">696148d8bb643392cffb3d61</guid><category><![CDATA[Rybelsus]]></category><category><![CDATA[Novo Nordisk]]></category><category><![CDATA[Semaglutide]]></category><pubDate>Fri, 09 Jan 2026 18:46:50 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_37675e2f881e4a61b4704169dc914a19~mv2.png/v1/fit/w_1000,h_819,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item><item><title><![CDATA[If Semaglutide Can Do This, The World Changes]]></title><description><![CDATA[Original posted at obesity.news/  on Nov 22, 2025 There is something coming in the next few days in the GLP-1 world that feels bigger than anything we have covered on On The Pen. Bigger than the supply chain fights. Bigger than the PBM battles. Bigger than the access wars. Something that reaches into the softest parts of the human experience. Memory. Identity. The fear of losing ourselves before losing our lives. In the next couple of weeks, the results from the Evoke and Evoke+ trials are...]]></description><link>https://www.onthepen.com/post/if-semaglutide-can-do-this-the-world-changes</link><guid isPermaLink="false">696146b0e434ecc89aa8db56</guid><category><![CDATA[Advocacy]]></category><category><![CDATA[Trials]]></category><category><![CDATA[Opinion]]></category><pubDate>Fri, 09 Jan 2026 18:26:46 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/60489a_dcf0b03628684e61adf4acf09b3bb461~mv2.jpg/v1/fit/w_1000,h_699,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Dave Knapp</dc:creator></item></channel></rss>